title: The impact of risk factors for atherosclerosis on the vasomotor effects of inhibition of nitric oxide synthesis in patients with normal angiograms.
abstract: We assessed the impact of systematic risk factors on the vasomotor effects of inhibition of nitric oxide synthesis. N(G)-monomethyl-L-arginine (LNMMA) was infused intracoronarily at 4, 8 and 16 micromol/min followed by intracoronary bolus administration of 250 microg nitroglycerin. Computerized angiography was used to assess the changes in the diameter of coronary segments. During the LNMMA infusions there was no significant difference in LNMMA response between smokers and non-smokers (-5.5+/-0.8 and -6.6+/-0.6%, respectively) or between hypertensives and normotensives (-6.4+/-1.1 and -6.1+/-0.6%, respectively), but the response was less in hypercholesterolaemic patients (-4.5+/-0.7 vs. -8.0+/-0.6%, p<0.05). Thus, the reduced nitric oxide activity is related to hypercholesterolaemia but not to smoking and hypertension.
authors: Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, Greece.
authors: C
authors: C
authors: Tentolouris
authors: D
authors: D
authors: Tousoulis
authors: G
authors: G
authors: Davies
authors: C
authors: C
authors: Stefanadis
authors: A
authors: A
authors: Trikas
authors: G
authors: G
authors: Goumas
authors: P
authors: P
authors: Toutouzas
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000150:complications; D007261:Infusions, Intra-Arterial; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000096:biosynthesis*; D005996:Nitroglycerin / Q000008:administration & dosage*; D012016:Reference Values; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects; D019323:omega-N-Methylarginine / Q000008:administration & dosage*
chemical_list: D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D005996:Nitroglycerin